证券代码：000028 、200028 证券简称：国药一致、一致B 公告编号：2024-43 国药集团一致药业股份有限公司 关于变更会计师事务所的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 国药集团一致药业股份有限公司（以下简称"公司"）于2024年9 月25日以通讯表决方式召开了第十届董事会2024年第一次临时会议， 会议审议通过了《关于改聘公司2024年度财务报告审计机构和内部控 制审计机构的议案》，同意改聘天健作为公司2024年度财务报告审计 机构和内部控制审计机构，该议案尚需提请公司股东大会审议。现将 拟聘任的会计师事务所名称：天健会计师事务所（特殊普通合伙） （以下简称"天健"） 原聘任的会计师事务所名称：普华永道中天会计师事务所（特殊 普通合伙）（简称"普华永道中天"）。 变更会计师事务所的简要原因及前任会计师的异议情况：根据《国 有企业、上市公司选聘会计师事务所管理办法》及《公司章程》 等相关规定，结合市场信息，基于审慎性原则，并综合考虑本公 司现有业务状况、发展需求及整体审计需要，经公司董事会风险 内控与审计委员会决议，拟改聘天健为公 ...

国药集团一致药业股份有限公司（以下简称"公司"）第十届董事 会2024年第一次临时会议于2024年9月18日以电话、传真和电子邮件 方式发出通知和文件材料，会议于2024年9月25日以通讯表决方式召 开。应参加会议董事9名，实际出席会议董事9名。会议召开程序符合 《公司法》、《公司章程》的有关规定。 本次会议审议通过了《关于改聘公司2024年度财务报告审计机构 和内部控制审计机构的议案》（具体内容详见当日公告及巨潮资讯网 http://www.cninfo.com.cn），同意改聘天健会计师事务所（特殊普通合 伙）作为公司2024年度财务报告审计机构和内部控制审计机构。 本议案须提交公司股东大会审议，股东大会召开时间另行通知。 本议案经公司第十届董事会风险内控与审计委员会2024年第三 次会议审议通过，并同意将该议案提交公司董事会审议。 证券代码：000028 、200028 证券简称：国药一致、一致B 公告编号：2024-42 国药集团一致药业股份有限公司 第十届董事会2024年第一次临时会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 表决结果 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook on its stock performance [3][4] Core Views - The company's overall performance is under pressure, but its distribution business remains relatively stable [3] - The retail segment is facing challenges due to industry policy changes, increased competition, and internal adjustments, leading to a significant decline in profitability [3] - The company's distribution business shows steady revenue growth, but profits have slightly declined due to delayed receivables and increased funding costs [3] - The retail segment, represented by "Guoda Pharmacy," experienced a 9.3% YoY decline in revenue and a 104.8% YoY drop in net profit in H1 2024 [3] - The company has maintained a steady pace of store expansion, with 18,602 stores as of June 30, 2024, and a net increase of 186 stores in H1 2024 [3] Financial Performance - In H1 2024, the company reported revenue of 37.79 billion yuan, a 1.6% YoY decrease, and a net profit of 740 million yuan, a 10.5% YoY decline [3] - The distribution business generated 27.08 billion yuan in revenue, a 2.1% YoY increase, but net profit fell by 1.5% to 520 million yuan [3] - The retail segment reported a net loss of 14 million yuan, a 107.5% YoY decline in net profit attributable to the parent company [3] - The company's gross margin decreased by 0.6 percentage points YoY to 11.0%, with the retail segment's gross margin dropping by 2.1 percentage points to 22.7% [4] Profit Forecast and Valuation - The report forecasts net profits of 1.78 billion yuan, 2.01 billion yuan, and 2.28 billion yuan for 2024, 2025, and 2026, respectively, with growth rates of 11%, 13.1%, and 13.8% [4] - The current stock price corresponds to a PE ratio of 8X, 7X, and 6X for 2024, 2025, and 2026, respectively [4] - The company's ROE is expected to improve slightly, from 9.2% in 2023 to 9.7% in 2026 [5] Market Performance - The company's stock price closed at 24.79 yuan on September 3, 2024, with a year-to-date high of 40.79 yuan and a low of 24.69 yuan [5] - The company's total market capitalization stands at 13 billion yuan [5]

证券代码：000028、200028 证券简称：国药一致、一致B 国药集团一致药业股份有限公司 投资者关系活动记录表 编号：2024 - 02 | --- | --- | --- | --- | --- | |--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Investment Rating - The report maintains a "Buy" rating for the company [2][3][4]. Core Views - The company's performance is expected to grow steadily due to external environment improvements and ongoing strategic optimizations, despite facing temporary pressure on distribution and retail growth [2]. - The company achieved revenue of 37.786 billion yuan in H1 2024, a decrease of 1.57%, and a net profit of 743 million yuan, down 10.45% [3]. - The report has adjusted the EPS forecast for 2024-2026 to 2.98, 3.33, and 3.73 yuan, respectively, and has lowered the target price to 30.99 yuan [3]. Financial Summary - In H1 2024, the distribution business generated revenue of 27.079 billion yuan, an increase of 2.11%, while net profit was 5.23 billion yuan, a decrease of 1.48% [3]. - The retail segment, represented by Guoda Pharmacy, reported revenue of 11.2 billion yuan in H1 2024, down 9.3%, with a significant decline in net profit to -14 million yuan [3]. - The company is focusing on improving operational quality and profitability through strategic optimizations in both distribution and retail sectors [3]. Future Outlook - The company anticipates steady growth in retail revenue as sales of cold medicines stabilize and the number of coordinated stores increases [3]. - The financial forecasts indicate a gradual increase in total revenue from 80.003 billion yuan in 2024E to 93.184 billion yuan in 2026E, with net profit expected to rise from 1.656 billion yuan to 2.078 billion yuan over the same period [4][10].

专业股份有限公司 | | | 单位:人民币元 | | --- | --- | --- | | 项目 | 期末余额 | 期初余额 | | 流动资产: | | | | 货币资金 | 6,006,725,421.46 | 6,502,347,869.02 | | 结算备付金 | | | | 拆出资金 | | | | 交易性金融资产 | | | | 衍生金融资产 | | | | 应收票据 | 604,216,664.64 | 1,150,180,377.30 | | 应收账款 | 22,459,134,687.56 | 18,160,331,460.14 | | 应收款项融资 | 938,540,327.75 | 913,977,078.31 | | 预付款项 | 505,217,479.33 | 620,002,738.38 | | 应收保费 | | | | 应收分保账款 | | | | 应收分保合同准备金 | | | | 其他应收款 | 802,968,004.99 | 809,010,983.64 | | 其中:应收利息 | | | | 应收股利 | 70,380,000.00 | | | 买入返售金融资产 | ...

国药集团一致药业股份有限公司 关于对国药集团财务有限公司的风险持续评估报告 通过查验国药集团财务有限公司（以下简称国药财务公司）《金 融许可证》《企业法人营业执照》等证件资料，并审阅了国药财务公 司截至2024年上半年的财务报告以及风险指标等必要信息，对国药财 务公司的经营资质、业务和风险状况进行了评估，具体情况报告如下： 一、国药财务公司基本情况 国药财务公司成立于2012年2月，是经原中国银行业监督管理委 员会批准成立的非银行金融机构。 企业名称：国药集团财务有限公司 注册地址：北京市海淀区知春路20号 法定代表人：杨珊华 金融许可证机构编码：L0145H211000001 统一社会信用代码：9111000071783212X7 目前国药财务公司注册资本金为人民币220,000万元，股权结构 如下表所示： | 序号 | 股东名称 | 出资额（万元） | 持股比例 | | --- | --- | --- | --- | | 1 | 中国医药集团有限公司 | 116,105 | 52.7750% | | 2 | 中国生物技术股份有限公司 | 69,895 | 31.7705% | | 3 | 中国中药有限公司 ...

Financial Performance - The company's operating revenue for the reporting period was ¥37,785,980,620.95, a decrease of 1.57% compared to the same period last year[11]. - The net profit attributable to shareholders was ¥743,487,174.84, reflecting a decline of 10.45% year-on-year[11]. - Basic earnings per share were ¥1.34, down 10.07% from ¥1.49 in the previous year[11]. - The total operating revenue for the first half of 2024 was CNY 37,785,980,620.95, a decrease of 1.57% compared to CNY 38,387,531,548.02 in the same period of 2023[124]. - The company reported a significant decrease in net profit for Guoyao Holdings Guoda Pharmacy Co., Ltd. by 104.81% due to industry policy changes and increased market competition[58]. - The total comprehensive income for the first half of 2024 was CNY 770,040,713.52, compared to CNY 1,029,395,669.22 in the first half of 2023, reflecting a decline of approximately 25.1%[125]. - The company reported a decrease in retained earnings of 378,464,252.36 RMB during the current period[143]. Cash Flow and Liquidity - The net cash flow from operating activities decreased by 37.47%, amounting to ¥929,377,508.78[11]. - The company's cash and cash equivalents saw a drastic decline of 9,591.84%, resulting in a net decrease of approximately ¥288.04 million[43]. - Cash inflow from financing activities totaled CNY 32,633,569,658.47, compared to CNY 26,250,517,069.07 in the same period last year, marking an increase of approximately 24.5%[132]. - The total cash and cash equivalents at the end of the period amounted to CNY 4,194,927,060.45, up from CNY 3,553,777,940.76 at the end of the previous year[132]. Assets and Liabilities - Total assets increased by 8.06% to ¥51,405,241,387.83 compared to the end of the previous year[11]. - The accounts receivable amounted to ¥22,459,134,687.56, representing 43.69% of total assets, an increase of 5.51% from the previous year[48]. - Total liabilities increased to CNY 30.06 billion from CNY 26.59 billion, reflecting a growth of about 13.3%[119]. - The company's total equity attributable to shareholders rose to CNY 17.78 billion from CNY 17.41 billion, an increase of approximately 2.1%[119]. Market and Economic Environment - The company noted a 5.0% year-on-year growth in China's GDP for the first half of 2024, indicating a stable economic environment[15]. - The retail pharmacy market size in China was approximately CNY 217.8 billion for January to May 2024, showing a year-on-year decline of 3.7%[18]. - The regulatory environment in the pharmaceutical industry is tightening, with ongoing reforms and price governance impacting the retail sector significantly[17]. Strategic Initiatives - The company is focusing on transforming its retail model to enhance service quality and reduce reliance on individual account medical insurance payments[19]. - The company aims to integrate distribution and logistics to create a leading supply chain value system in the pharmaceutical distribution sector[20]. - The company is focusing on digital transformation, having launched a business value analysis tool and a shared collaboration platform to enhance data integration and decision-making[28]. - The company has implemented a "one body, two wings" strategy to innovate and transform its business model, integrating traditional distribution with retail and innovative services[26]. Risk Management - There are no significant risks that could materially affect the company's operations during the reporting period[2]. - The company has detailed potential risks and corresponding countermeasures in the report[2]. - The company faces significant policy risks, including declining sales margins due to centralized procurement and increased competition from online pharmacies[61]. Research and Development - Research and development expenses increased by 7.72% to ¥12.97 million compared to ¥12.04 million in the previous year[43]. - The company is focused on enhancing its R&D capabilities to drive innovation and improve product offerings[95]. Shareholder Information - The total number of shares is 556,565,077, with 98.71% being unrestricted shares[105]. - The largest shareholder, China National Pharmaceutical Group Co., Ltd., holds 56.06% of the shares, totaling 311,999,988 shares[106]. - The company has not undergone any changes in its controlling shareholder or actual controller during the reporting period[113]. Environmental Compliance - The company has established environmental pollution prevention facilities for wastewater treatment, ensuring compliance with pollution discharge standards[70]. - The company has completed the application and renewal of pollution discharge permits, all of which are currently valid[71].

证券代码：000028、200028 证券简称：国药一致、一致B 公告编号：2024-38 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 国药集团一致药业股份有限公司（以下简称"公司"）第十届董 事会第二次会议于2024年8月16日以电话电子邮件方式发出通知和文 件材料，会议于2024年8月27日以现场会议结合视频会议方式在上海 召开。应参加会议董事9名，实际出席会议董事9名。公司监事及高级 管理人员列席本次会议。董事长吴壹建先生主持本次董事会。会议的 召集召开程序符合《公司法》《公司章程》的有关规定。 二、董事会会议审议情况 1. 审议通过了《公司 2024 年半年度报告及摘要》 本项议案的表决结果：同意 9 票，反对 0 票、弃权 0 票。（具体 内容详见当日公告及巨潮资讯网 http://www.cninfo.com.cn） 本议案经第十届董事会风险内控与审计委员会 2024 年第二次会 议审议通过。 2. 审议通过了《关于 2024 年对外捐赠预算申请的议案》 国药集团一致药业股份有限公司 第十届董事会第二次会议决议公告 5. ...

证券代码：000028、200028 证券简称：国药一致、一致B 公告编号：2024-39 二、监事会会议审议情况 1. 本次会议以"同意 3 票；反对 0 票；弃权 0 票"审议通过了 《公司 2024 年半年度报告及摘要》。 2. 本次会议以"同意 3 票；反对 0 票；弃权 0 票"审议通过了 《关于对国药集团财务有限公司的风险持续评估报告》。 第十届监事会第二次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 国药集团一致药业股份有限公司（以下简称"公司"）第十届监事 会第二次会议于 2024 年 8 月 16 日以电话电子邮件方式发出通知和文 件材料，会议于 2024 年 8 月 27 日以现场会议结合视频会议方式在上 海召开。会议应参会监事 3 名，实际参会监事 3 名。监事会主席文德 镛先生主持本次监事会。本次会议的召集、召开程序符合《公司法》、 《公司章程》及《监事会议事规则》的有关规定。 国药集团一致药业股份有限公司 特此公告。 国药集团一致药业股份有限公司监事会 2024 年 8 月 29 日 ...